All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does pre-transplant measurable residual disease (MRD) affect outcome in AML?
How does pre-transplant MRD affect outcome in AML?
In this video, Nagler discusses how pre-transplant MRD, the most important predictive factor, affects the outcome of transplantation in AML. Patients who are MRD-negative pre-transplant have a lower relapse rate, and better leukemia-free and overall survival; however, MRD does not appear to affect transplant-related mortality. Nagler goes on to describe the results of a study investigating whether MRD dictates transplant results in patients that received post-transplant cyclosporine as graft-versus-host disease prophylaxis.
EHA 2019 | Should we use PTCy or ATG as GvHD prophylaxis in haploidentical stem cell transplantation?
Arnon Nagler from the Tel Aviv Univesity, Tel Aviv, IL, discusses whether prophylactic post-transplant cyclophosphamide (PTCy) or anti-thymocyte...
Arnon Nagler | EBMT 2019 | Haploidentical hematopoietic transplantation: current status and future perspectives
Arnon Nagler, from Tel Aviv University, IL, discusses haploidentical hematopoietic transplantation: current status and future perspectives
Subscribe to get the best content related to AML delivered to your inbox